source
- Experts say Angelman syndrome drug failure leaves hope for similar antisense therapiesUltragenyx announced that its late-stage trial of an experimental Angelman syndrome drug did not meet its primary endpoints, marking a setback for the rare-disease community. Researchers such as M…
- Truist sees biotech rebound as M&A hits $136B and XBI climbs 34% in H1Truist Securities says the biotech sector is regaining momentum after a prolonged post‑pandemic slowdown, driven by rising merger activity, returning venture capital and easing policy risks. The S…